Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
The RALU study (Rahbar et al., PMID 36302656) really is quite a small 49-patient cohort study looking at the one-way question of the safety of PSMA-Lu177 in carefully selected patients who had adequate marrow function after both an ARSI, taxane chemo, and radium-223. While these selected patients to...
Would you consider omitting adjuvant radiation in a very elderly patient with a small triple negative breast cancer?
Elderly isn't quantitative or qualitative. Would want to know performance status/life expectancy.Occasionally, patients have had enough and they don't want further treatment after surgery.I presume they also will not receive chemotherapy. If breast cancer takes her life, it will be because of distan...
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Thanks for the important question. This is a nice but also challenging situation given, at this time, we do not have evidence for organ preservation with chemotherapy alone. Nonetheless, the PROSPECT trial did show approximately 20% of patients indeed achieved pathological compete response (was quit...
Is there a rationale for treating medically inoperable stage I-III breast cancer patients with RT alone?
We treated stage III patients with "radical radiotherapy" with or without chemotherapy when I was a resident in the early 1980s, since they were considered SURGICALLY inoperable then. However, very high doses were needed (75-80 Gy to the primary using external beam followed by interstitial implants)...
How would you treat a patient with synchronous node positive prostate cancer (T3bN1M0) and oligometastatic rectosigmoid cancer (T4aN1M1) with a solitary liver metastasis?
I reached out to my colleague, Dr. @Dr. First Last, a radiation oncologist and co-director of the Prostate Cancer Center at Dana Farber, who has expertise in both genitourinary and gastrointestinal cancers for his thoughts on this question. Here is his answer: Recognizing that the rectal cancer is l...
Is it necessary to treat pelvic lymph nodes for muscle invasive bladder cancer?
You're correct that there is considerable variability in the target used in bladder radiotherapy. We performed a survey of radiation oncologists regarding bladder cancer radiotherapy patterns and found that ~60% use a "small pelvis," ~30% use a true whole pelvis, and ~10% treat the bladder only [1]....
What do your treatment volumes include when treating a resected mucoepidermoid carcinoma of the parotid gland with close, but negative, margins where recurrence would require sacrifice of branches of the facial nerve?
Following general principles, the 3 targets are tumor bed, operative bed and subclinical non-operative bed. Ideally, the patient has preoperative imaging, as unfortunetly it is still common that these pts are operated without oncologic assessment. As the scar is part of the operative bed, it is cove...
Do you routinely offer a stereotactic boost to patients with bulky (>3cm) residual brain metastasis after whole brain radiation for multiple brain metastases?
In general, bulky tumors are resected out. If for some reason a patient with a bulky tumor does receive WBRT for a bulky tumor, I would wait a month or two after for a repeat MRI. If the tumor does shrink it should provide some room to dose escalate.
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
In the ADRIATIC study, stage I or II limited-stage SCLC comprised only about 12% of patients randomized. The point estimate of HR regarding survival benefit was 0.92, with a wide confidence interval exceeding 1.0 (upper range more than 2). I do not recommend durvalumab consolidation for those with s...
How do you approach radiation treatment of extramammary Paget's disease of vulva, diffusely involving the urothelium and the periurethral glands?
Very unusual case. Presuming it has invasive disease, would also check HER2/neu status to see if there is any value of indication with chemo and anti-HER2/neu therapy. Will plan definitive chemo RT treating vulva, vagina, urethra, and bladder (if involved) to 66-70 Gy to gross disease and prophylact...